Houston-based Texas Medical Center launched its third five-month accelerator program in partnership with Innovate UK, welcoming eight medical device startups to its Innovation Factory on Sept. 8.
The cohort includes companies focused on behavioral health, maternal trauma and drug delivery, emergency monitoring, dementia and other neurological conditions, and precision surgical tools. The program is part of the Innovate UK Global Incubator Programme and the TMC–United Kingdom BioBridge.
TMC said the program will provide startups with access to clinical trial infrastructure, mentorship, and resources to support U.S. market entry and commercialization efforts.
Participating startups include CareLoop Health and Safehinge Primera, which are developing technologies to support behavioral health and risk prevention. PeriPear and Calla Lily are advancing maternal health solutions through wearable and drug delivery devices, while ACT Medical is developing tools to reduce fatal blood loss from knife wounds.
Additional participants are OmniBuds, a device monitoring all five vital signs continuously; Neu Health, a platform for monitoring symptoms in Parkinson’s and dementia patients; and Nami Surgical, which is creating miniaturized ultrasonic scalpels for robotic procedures.
“We are excited to welcome this new cohort and look forward to seeing their innovations make a difference at TMC and beyond,” said Tom Luby, chief innovation officer of the Texas Medical Center. “Since the launch of our first specialized accelerator through our Biobridge partnerships, we’ve seen commitment and ingenuity from entrepreneurs tackling complex medical challenges. They understand first-hand the realities of these conditions, and TMC provides a unique place to brainstorm, bring ideas to life, test, and commercialize solutions for impact here and around the world.”
